Immuno-fluorescent Labeling of Microtubules and Centrosomal Proteins in Ex Vivo Intestinal Tissue and 3D In Vitro Intestinal Organoids
December 13th, 2017
17.3K views
We present protocols for isolation of intestinal 3D structures from in vivo tissue and in vitro basement matrix embedded organoids, and detail different fixation and staining protocols optimized for immuno-labeling of microtubule, centrosomal, and junctional proteins as well as cell markers including the stem cell protein Lgr5.
Overview
This article presents protocols for isolating intestinal 3D structures from in vivo tissue and in vitro organoids. It details fixation and staining protocols optimized for immuno-labeling various proteins and cell markers.
Key Study Components
Area of Science
- Cell Biology
- Developmental Biology
- Neuroscience
Background
- 3D organoids are valuable models for studying biological processes.
- Localizing proteins in 3D structures is more complex than in 2D cultures.
- Fixatives must preserve 3D architecture and antigenicity.
- Methods can be applied to both in vitro and ex vivo tissues.
Purpose of Study
- To isolate and label intestinal organoids for biological research.
- To optimize fixation and immunolabeling protocols.
- To demonstrate the effectiveness of the methods in preserving organoid structure.
Methods Used
- Isolation of intestinal crypts and villi.
- Formaldehyde methanol fixation of organoids.
- Immunolabeling of microtubules and centrosomal proteins.
- Use of secondary antibodies for enhanced labeling.
Main Results
- Successful isolation of free-moving organoids.
- Preservation of 3D structures during fixation.
- Effective immunolabeling of targeted proteins.
- Demonstration of the procedure's applicability in research.
Conclusions
- The protocols enable detailed study of intestinal organoids.
- Methods are adaptable for various research applications.
- Future studies can build on these techniques for deeper insights.
Frequently Asked Questions
What are intestinal organoids?
Intestinal organoids are 3D structures derived from intestinal stem cells that mimic the architecture and function of the intestine.
Why is fixation important in this study?
Fixation preserves the 3D structure of organoids and maintains the antigenicity of proteins for accurate labeling.
What proteins are targeted for immunolabeling?
The study focuses on microtubule, centrosomal, junctional proteins, and cell markers like Lgr5.
How long does it take to form organoids?
Organoids typically form after approximately five to seven days of incubation.
Can these methods be applied to other tissues?
Yes, the fixation and immunolabeling protocols can also be used for ex vivo isolated tissues.
What is the role of secondary antibodies?
Secondary antibodies enhance the detection of primary antibodies, improving the visibility of labeled proteins.
Executive Industry Relevance
Accurate localization of endogenous proteins in 3D intestinal models is critical for validating fluorescent-tagged constructs and ensuring reliable phenotypic readouts in preclinical drug discovery. This protocol enables preservation of delicate tissue architecture while maintaining antigenicity, supporting mechanistic de-risking of microtubule and centrosomal targets. It provides a reproducible workflow for target validation in disease-relevant intestinal systems, directly informing lead identification and predictive confidence in early discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of microtubule and centrosomal protein localization in physiologically relevant intestinal tissue and organoids.
- Operational Value: Supports functional target validation by confirming endogenous expression patterns prior to genetic manipulation or live imaging.
- Predictive Value: Reduces mechanistic ambiguity in target hypothesis testing through direct visualization of endogenous protein architecture.
Screening & Assay Development
- Assay Readiness: Generates fixed, labeled 3D intestinal models suitable for high-content imaging and quantitative protein localization assays.
- Reproducibility: Standardized fixation and immunolabeling workflow ensures consistent antigen preservation across batches for reliable screening outputs.
- Scalability: Compatible with basement matrix-embedded organoids, enabling platform reuse across multiple targets and experimental conditions.
Translational & Preclinical Research
- Disease Relevance: Applicable to intestinal organoid models used in studying gastrointestinal pathophysiology and drug response.
- Translational Continuity: Bridges ex vivo tissue validation with in vitro organoid systems, supporting cross-model target confirmation.
- Risk-Adjusted Advancement: Facilitates go/no-go decisions by verifying on-target effects in structurally preserved, antigenically intact models.
Pipeline & Workflow Integration
This method integrates into the discovery continuum from early target validation through preclinical evaluation, enabling reliable protein localization in intestinal models that inform lead optimization and mechanistic de-risking.
- Discovery Biology: Supports hypothesis testing by confirming endogenous microtubule and centrosomal protein localization in disease-relevant intestinal systems.
- Screening: Delivers assay-ready, immunolabeled 3D organoids with preserved structure for quantitative imaging-based compound evaluation.
- Analytics: Enables quantitative readouts of protein expression and subcellular distribution, aiding comparative analysis across treatment conditions.
- Translational Research: Ensures continuity between ex vivo tissue validation and in vitro organoid models, strengthening preclinical validity.
- Enterprise Reuse: Establishes a standardized, reusable immunofluorescent workflow applicable across multiple targets and intestinal disease models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through direct visualization of endogenous protein architecture in 3D intestinal models.
- Operational Value: Standardization, reproducibility, and scalability of fixation and immunolabeling across tissue and organoid systems.
- Strategic Value: Improved go/no-go decisions, capital efficiency, and reduced late-stage biological risk via early mechanistic de-risking.
- Portfolio Impact: Risk-adjusted prioritization of targets based on validated localization in physiologically relevant intestinal systems.
Implementation Considerations
- Expertise in tissue dissection, organoid handling, and immunofluorescence techniques.
- Access to cryogenic storage (-20°C) for formaldehyde-methanol fixation and centrifuge for pelleting steps.
- Standardization of washing, blocking, and antibody incubation protocols across teams to ensure reproducibility.
- Adaptation considerations for different intestinal regions (small intestine vs. colon) based on EDTA optimization for crypt/villi isolation.
- Practical limitations include hazardous fixative handling requiring PPE and containment, and potential organoid loss during matrix removal if pipetting is too aggressive.
Biopharma FAQs
Why is formaldehyde methanol fixation used for microtubule labeling in intestinal organoids?
The formaldehyde methanol fixation protocol preserves 3D organoid architecture while maintaining antibody antigenicity, enabling effective labeling of microtubules and centrosomal proteins like ninein. This dual preservation is critical for accurate subcellular localization studies in 3D models.
How does EDTA concentration affect isolation of intestinal crypts and villi for organoid generation?
Increasing EDTA concentration from 3 mM to 30 mM enables efficient detachment of villi and crypts from small intestine tissue, while 3 mM EDTA is sufficient for isolating colonic crypts. This optimization supports reliable isolation of intestinal epithelial structures for downstream organoid culture or direct fixation.
What quantitative measurements enable assessment of microtubule preservation in fixed intestinal organoids?
Immunolabeling allows visualization of stable apicobasal microtubules and end-binding proteins like EB1 along the microtubule lattice, providing qualitative and semi-quantitative assessment of structural preservation. Successful labeling indicates effective fixation and antigen retention.
Why are replication requirements important for immunolabeling workflows in multi-target studies?
Replication through repeated washing, centrifugation, and resuspension steps ensures consistent removal of unbound antibodies and reduces background noise, which is essential for reliable comparison across targets and experimental conditions in drug discovery programs.
What statistical analysis capabilities are required before implementing this immunofluorescent protocol in discovery pipelines?
Implementation requires capability for qualitative assessment of protein localization and subcellular patterning, supported by confocal imaging and standardized scoring of labeling efficiency across organoid populations to enable comparative analysis in target validation studies.
Chapters in this video
0:05
Title
1:41
Isolation of Intestinal Organoids from Basement Matrix Domes in 24-well Plates
3:20
Fixation of Isolated Organoids
4:22
Blocking, and Primary and Secondary Antibody Incubation
6:41
Mounting Isolated Organoids
7:39
Results: Isolation and Immunolabeling of Intestinal Organoids
8:55
Conclusion
